Reich Adam, Orda Alina, Wiśnicka Beata, Szepietowski Jacek C
Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Ul. Chalubinskiego 1, 50-368 Wroclaw, Poland.
Exp Dermatol. 2007 May;16(5):421-8. doi: 10.1111/j.1600-0625.2007.00544.x.
The aim of this study was to evaluate plasma levels of substance P (SP), calcitonin gene-related peptide (CGRP), vasoactive intestinal peptide (VIP) and neuropeptide Y (NPY) during psoriasis course.
Seventy-three patients with psoriasis and 32 healthy volunteers were included. Detailed demographic and disease anamnesis was obtained from every patient. The disease severity was assessed using the Psoriasis Area and Severity Index score. Plasma levels of SP, CGRP, VIP and NPY were measured radioimmunologically.
Plasma levels of SP and NPY did not significantly differ between patients with psoriasis and controls (median SP: 52.8 and 57.9 pg/ml, respectively; P = 0.32; median NPY: 8.5 and 8.2 pg/ml, respectively; P = 0.67). CGRP plasma concentration was significantly elevated in psoriatic individuals both before (median 43.1 pg/ml) and after treatment (median 45.4 pg/ml), in comparison with healthy donors (median 13.5 pg/ml; P < 0.01 and P = 0.03, respectively). Treatment did not significantly influence plasma CGRP levels (P = 0.3). Median VIP plasma concentration in psoriatics before treatment was significantly higher compared with healthy controls (medians 66.9 and 60.1 pg/ml, respectively; P = 0.04), but the therapy resulted in significant decrease in VIP plasma level (median 19.0 pg/ml; P < 0.001). In psoriatic patients significant correlations were noted between NPY and VIP (R = 0.34; P < 0.01), and VIP and CGRP plasma levels, both before (R = 0.28; P = 0.03) and after the treatment (R = 0.44; P < 0.01).
Based on our results and previous literature data it could be suggested that neuropeptides may be involved in the development of psoriatic lesions.
本研究旨在评估银屑病病程中P物质（SP）、降钙素基因相关肽（CGRP）、血管活性肠肽（VIP）和神经肽Y（NPY）的血浆水平。
纳入73例银屑病患者和32名健康志愿者。收集每位患者详细的人口统计学和疾病既往史。使用银屑病面积和严重程度指数评分评估疾病严重程度。采用放射免疫法测定血浆中SP、CGRP、VIP和NPY的水平。
银屑病患者与对照组之间SP和NPY的血浆水平无显著差异（SP中位数分别为52.8和57.9 pg/ml；P = 0.32；NPY中位数分别为8.5和8.2 pg/ml；P = 0.67）。与健康供者相比，银屑病患者治疗前（中位数43.1 pg/ml）和治疗后（中位数45.4 pg/ml）的CGRP血浆浓度均显著升高（健康供者中位数为13.5 pg/ml；P分别< 0.01和P = 0.03）。治疗对血浆CGRP水平无显著影响（P = 0.3）。银屑病患者治疗前VIP血浆浓度中位数显著高于健康对照组（中位数分别为66.9和60.1 pg/ml；P = 0.04），但治疗后VIP血浆水平显著降低（中位数19.0 pg/ml；P < 0.001）。在银屑病患者中，NPY与VIP之间（R = 0.34；P < 0.01）以及VIP与CGRP血浆水平之间，无论治疗前（R = 0.28；P = 0.03）还是治疗后（R = 0.44；P < 0.01）均存在显著相关性。
根据我们的研究结果和既往文献数据，提示神经肽可能参与银屑病皮损的发生发展。
